Arrowhead Pharmaceuticals Income Statement (2010-2025) | ARWR

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	32.81M	45.89M	38.28M	27.44M	151.81M	32.41M	31.57M	62.55M	146.27M	15.82M	16.10M	3.55M				2.50M	542.71M	27.77M	256.47M	264.03M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)	44.70M	59.33M	65.77M	65.77M	75.98M	72.18M	83.38M	83.69M	74.88M	94.76M	99.86M	116.49M	101.12M	152.43M	135.83M	137.00M	133.10M	162.37M	174.69M	177.20M
Selling, General & Administrative (Quarter)	16.35M	18.43M	37.40M	25.00M	34.27M	33.14M	32.03M	20.98M	23.22M	23.77M	24.57M	23.61M	25.07M	23.71M	26.38M	26.91M	28.41M	30.95M	37.68M	46.02M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)	61.04M	77.76M	103.17M	90.76M	110.25M	105.32M	115.41M	104.68M	98.10M	118.53M	124.43M	140.10M	126.19M	176.14M	162.20M	163.91M	161.51M	193.32M	212.37M	223.22M
Operating Income (Quarter)	-28.23M	-31.87M	-64.88M	-63.32M	41.55M	-72.91M	-83.83M	-42.13M	48.16M	-102.70M	-108.33M	-136.54M	-126.19M	-176.14M	-162.20M	-161.41M	381.20M	-165.55M	44.11M	40.81M
EBIT (Quarter)	-28.23M	-31.87M	-64.88M	-63.32M	41.55M	-72.91M	-83.83M	-42.13M	48.16M	-102.70M	-108.33M	-136.54M	-126.19M	-176.14M	-162.20M	-161.41M	381.20M	-165.55M	44.11M	40.81M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)	1.52M	1.28M	1.15M	1.16M	1.05M	1.24M	1.58M	2.68M	4.56M	4.17M	3.88M	2.80M	6.25M	6.50M	7.17M	7.60M	9.62M	11.02M	9.10M	9.69M
Other Non Operating Income (Quarter)	-0.11M	0.66M	0.36M	-0.71M	1.76M	-0.38M	0.09M	0.51M	0.01M	0.31M	0.72M	0.42M	0.19M	0.76M	-3.12M	0.34M	0.44M	-0.18M	4.66M	0.28M
Non Operating Income (Quarter)	-0.11M	1.94M	1.51M	-0.71M	2.81M	-0.38M	-3.36M	0.34M	-0.49M	0.31M	-0.66M	-2.14M	-0.81M	0.76M	-0.96M	0.34M	0.44M	-13.54M	-7.99M	-12.54M
Net income details
EBT (Quarter)	-26.82M	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-82.16M	-41.79M	47.68M	-103.38M	-108.99M	-138.69M	-127.00M	-173.98M	-172.80M	-175.12M	369.62M	-179.09M	36.12M	28.27M
Tax Provisions (Quarter)			0.00M				3.79M			0.74M	2.02M	-3.31M			0.55M	0.10M	1.75M	-0.44M	20.00M	0.03M
Profit After Tax (Quarter)	-26.82M	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.81M	47.68M	-104.12M	-107.02M	-135.38M	-127.00M	-170.79M	-180.74M	-173.09M	367.86M	-178.65M	8.00M	28.24M
Equity Income (Quarter)
Income from Non-Controlling Interests (Quarter)							-0.43M	-0.49M	-1.00M	-1.18M	-1.34M	-2.51M	-1.70M	-3.18M	-2.81M	-2.13M	-2.58M	-3.41M	39.87M	-2.57M
Income from Continuing Operations (Quarter)	-26.82M	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.34M	-175.22M	367.86M	-178.65M	16.12M	28.24M
Consolidated Net Income (Quarter)	-26.82M	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.34M	-175.22M	367.86M	-178.65M	16.12M	28.24M
Income towards Parent Company (Quarter)	-26.82M	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.34M	-175.22M	367.86M	-178.65M	16.12M	28.24M
Net Income towards Common Stockholders (Quarter)	-26.82M	-29.92M	-63.37M	-62.87M	44.37M	-72.05M	-85.94M	-41.79M	47.68M	-104.12M	-111.02M	-135.38M	-127.00M	-173.98M	-173.34M	-175.22M	367.86M	-178.65M	16.12M	28.24M
Additional items
EPS (Basic) (Quarter)	-0.26	-0.29	-0.61	-0.60	0.42	-0.68	-0.81	-0.39	0.46	-0.96	-1.02	-1.24	-1.02	-1.38	-1.37	-1.39	2.78	-1.26	-0.18	0.22
EPS (Weighted Average and Diluted) (Quarter)	-0.26	-0.29	-0.61	-0.60	0.41	-0.68	-0.81	-0.39	0.45	-0.96	-1.02	-1.24	-1.02	-1.38	-1.37	-1.39	2.75	-1.26	-0.18	0.22
Shares Outstanding (Weighted Average) (Quarter)	103.30M	103.57M	103.75M	104.53M	105.55M	105.27M	105.43M	106.04M	106.76M	107.00M	106.75M	107.42M	115.31M	118.26M	119.78M	124.85M	133.36M
Shares Outstanding (Diluted Average) (Quarter)	103.30M	103.57M	103.75M	104.53M	107.93M	105.75M	105.43M	106.04M	108.14M	107.00M	106.75M	107.42M	123.28M	118.26M	119.78M	124.85M	130.26M
EBITDA (Quarter)	-26.91M	-29.96M	-63.51M	-62.91M	44.37M	-72.08M	-85.94M	-41.93M	47.60M	-104.20M	-113.83M	-133.41M	-126.84M	-173.87M	-167.61M	-175.83M	368.12M	-177.69M	17.21M	28.50M
Interest Expenses (Quarter)								2.85M	5.06M	5.16M	5.26M	5.37M	7.24M	5.09M	14.65M	21.65M	21.64M	24.38M	21.69M	22.50M
Tax Rate (Quarter)			0.00%				-4.61%			-0.72%	-1.86%	2.39%			-0.32%	-0.06%	0.47%	0.24%	55.37%	0.10%

Research Tools

Arrowhead Pharmaceuticals Income Statement (2010-2025) | ARWR

Create an account

Sign In

Reset Password